Chemotherapy and Erlotinib for Lung Cancer With Low Abundance Epidermal Growth Factor Receptor Mutation

NCT02095782 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

10

Enrollment

OTHER

Sponsor class

Stopped Because of the very slow enrollment, this study was stopped.

Conditions

Non-small-cell Lung Cancer

Interventions

DRUG: Intercalated combination of chemotherapy and erlotinib

Sponsor

Guangdong Association of Clinical Trials